A Case of Favorable Responses after Gefitinib in a Patient with EGFR Mutated Adenosquamous Lung Carcinoma
Nam-Jun CHO; Ho-Sung LEE; Si-Hyong JANG; Jae-Sung CHOI; Ju-Ock NA; Ki-Hyun SEO; Yong-Hoon KIM; Hyo-Chul KANG; Dae-Yeon KIM.
Soonchunhyang Medical Science
; : 123-127, 2013.
Artículo
en Inglés
| WPRIM | ID: wpr-147411
In patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are used as first treatment option. Because adenosquamous carcinoma (ASC) is a rare histologic subtype, evidences about EGFR-TKIs as first treatment option for advanced ASC are lacking. We report a case of an advanced ASC patient with the EGFR mutation, who showed good responses during 4-month treatment with gefitinib. And we will review about a necessity of EGFR mutation test and efficacy of EGFR-TKIs in ASC patients from the recent studies.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados